^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CYB5R2 (Cytochrome B5 Reductase 2)

    i
    Other names: CYB5R2, Cytochrome B5 Reductase 2, NADH-Cytochrome B5 Reductase 2, B5R.2, Cytochrome B5 Reductase B5R.2
    Associations

    News

    Trials
    5ms
    Integration of eQTL and GEO Datasets to Identify Genes Associated with Breast Ductal Carcinoma In Situ. (PubMed, Curr Issues Mol Biol)
    Thirteen genes were associated with DCIS progression, and six genes were validated in the cell experiments. KEGG and GO analyses highlight TME's role in early breast cancer, enhancing understanding of DCIS occurrence and aiding identification of high-risk tumors.
    Journal
    |
    PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • CYB5R2 (Cytochrome B5 Reductase 2) • GPX3 (Glutathione Peroxidase 3) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2)
    7ms
    ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein. (PubMed, Redox Biol)
    Meanwhile, ATF7IP stabilizes the antioxidant sensor Parkinsonism-associated deglycase (PARK7) protein which preserves the transsulfuration pathway to produce GSH, also leading to the inhibition of Sorafenib-induced ferroptosis. In conclusion, our findings identify ATF7IP as a critical ferroptosis inhibitor and represent ATF7IP as a novel therapeutic target for Sorafenib-based combination therapies of hepatocellular carcinoma.
    Journal
    |
    ATF7IP (Activating Transcription Factor 7 Interacting Protein) • CYB5A (Cytochrome B5 Type A) • SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) • CYB5R2 (Cytochrome B5 Reductase 2) • TCF7 (Transcription Factor 7)
    |
    sorafenib
    over2years
    GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. (PubMed, Drug Resist Updat)
    GATA3 promotes doxorubicin resistance by inhibiting CYB5R2-mediated iron metabolism and ferroptosis. Therefore, patients with breast cancer who display high GATA3 expression do not benefit from doxorubicin-based NAC regimens.
    Journal
    |
    GATA3 (GATA binding protein 3) • CYB5R2 (Cytochrome B5 Reductase 2)
    |
    doxorubicin hydrochloride